Search Within

Martin Stuart Tallman

  1. "2019"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (23)
  3. Review (6)
  4. Editorial (3)
  5. Guidelines (2)
Groups
  1. Adult Leukemia (63)
  2. Center for Hematologic Malignancies (63)
  3. Department of Medicine (63)
  4. Hematologic Malignancies, Division of (63)
  5. Weinberg Fellows (15)
  6. Executive Committee, Center for Hematologic Malignancies (13)

More Groups

People
  1. Eytan Stein (16)
  2. Ross Levine (11)
  3. Aaron Goldberg (9)
  4. Sean Devlin (7)
  5. Christopher Famulare (6)
  6. Jacob Glass (6)

More People

Years
  1. 2019 (63)
Publications
  1. Blood (27)
  2. Blood Advances (4)
  3. Leukemia and Lymphoma (4)
  4. Leukemia Research (3)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Cancer Discovery (2)

More Publications

Publishers
  1. American Society of Hematology (31)
  2. Taylor & Francis Group (5)
  3. American Association for Cancer Research (4)
  4. Elsevier Inc. (4)
  5. Elsevier Ltd (3)
  6. Nature Publishing Group (3)

More Publishers

Results (63)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): Final results
    Meeting Abstract

    Zeidan, A. M.; DeAngelo, D. J.; Palmer, J. M.; Seet, C. S.; Tallman, M. S.; Wei, X.; Li, Y. F.; Hock, N.; Burgess, M. R.; Hege, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Tolerability and efficacy of crenolanib and cytarabine/anthracycline chemotherapy in older patients (aged 61 to 75) with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
    Meeting Abstract

    Wang, E. S.; Griffiths, E. A.; Walter, R. B.; Tallman, M. S.; Goldberg, A. D.; Messahel, B.; Stone, R. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Arsenic trioxide abrogate MN1 mediated RA-resistance in acute promyelocytic leukemia
    Meeting Abstract

    Pereira-Martins, D. A.; Coelho-Silva, J. L.; Weinhäuser, I.; Koury, L. C. A.; Melo, R. A. M.; Bittencourt, R.; Pagnano, K. B.; Pasquini, R.; Nunes, E. C.; Fagundes, E. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Shukla, M.; Salcedo, J. M.; Vemuri, S.; Kinoshita, J. C.; Smith, M. D.; Winer, E. S.; Abdel-Wahab, O.; Tallman, M. S.
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical and functional studies reveal that TP73 isoforms levels are associated with prognosis and RA-resistance in acute promyelocytic leukemia
    Meeting Abstract

    Rojas, C. A. O.; Pereira-Martins, D. A.; Weinhäuser, I.; Almeida, L. Y.; Bianco, T. M.; Figueiredo-Pontes, L. L.; Koury, L. C. A.; Melo, R. A. M.; Bittencourt, R.; Pagnano, K. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia
    Meeting Abstract

    Menghrajani, K.; Cai, S. F.; Devlin, S. M.; Armstrong, S. A.; Piekarz, R.; Rudek, M.; Tallman, M. S.; Stein, E. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3 mutated acute myeloid leukemia (AML)
    Meeting Abstract

    Luger, S. M.; Sun, Z.; Loghavi, S.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Pratz, K. W.; Litzow, M.
    Blood (2019)

    Fulltext@MSK | Save
  • Acute leukemia with lineage infidelity: Mixed phenotype AML exhibits a distinct immunophenotype with clinical features overlapping mixed phenotype acute leukemia
    Meeting Abstract

    Kresch, M. P.; Xiao, W.; Menghrajani, K.; Famulare, C.; Patel, M. A.; Baik, J.; Roshal, M.; Levine, R. L.; Tallman, M. S.; Glass, J. L.
    Blood (2019)

    Fulltext@MSK | Save
  • Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia patients at first relapse: A multi-center outcomes analysis
    Meeting Abstract

    Hu, R.; Wei, W.; Gonter-Aubin, K.; Pinilla Ibarz, J.; Kabel, C. C.; Mato, A. R.; Madanat, Y. F.; Khajavian, S.; Shadman, M.; Hanlon, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study
    Meeting Abstract

    Foran, J. M.; DiNardo, C. D.; Watts, J. M.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A.; Stone, R. M.; Patel, P. A.; more...
    Blood (2019)

    Fulltext@MSK | Save